Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be at least 18-years-old~* ECOG performance status 0-2~* Patients must have pathology-proven metastatic urothelial carcinoma, with tissue sampling of at least the primary tumor. Tissue sampling of each presumed metastatic site is not necessary, provided that the patient already has a confirmed diagnosis of urothelial cancer.~* Patients must be on immune checkpoint inhibitor therapy with radiographic scans to verify oligo-progression of at least one and ≤ 6 sites of disease per RECIST 1.1.~  * Any of the currently FDA-approved PD-1/PD-L1 inhibitors are allowed. These include pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab.~ * At least 1 metastatic lesion must show stable disease, partial response or complete response per RECIST 1.1.~* Patients must be able to understand and willing to sign written informed consent.~* Patients must have acceptable tolerability of ongoing therapy as decided by the treating medical oncologist.~* Patients must have a desire to continue ongoing therapy.~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.~* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~  * Has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~ * Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~Exclusion Criteria:~* Inability to receive further immune checkpoint inhibitor therapy~* Anticipated survival of fewer than 12 weeks~* Daily steroid requirement of \> 10 mg prednisone or prednisone-equivalent. Steroid replacement therapy for adrenal insufficiency is permitted.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.~* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAbR 6 measurable lesions (Type: EXPERIMENTAL): PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)

Based on this trial design, predict the completion outcome and termination type (if applicable).